The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

banner

Gilead Sciences Announces Notification of ANDA Filing for Tamiflu

08-Feb-2011 | Source : AG-IP News | Visits : 7257

FOSTER CITY, CA - Gilead Sciences Inc. announced in a press release receipt of a Paragraph IV Certification Notice Letter advising that Natco Pharma Limited submitted an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Tamiflu(R) (oseltamivir phosphate) 75 mg capsules.

In the Notice Letter, Natco alleges that a patent associated with Tamiflu - US Patent Number 5,763,483 - owned by Gilead Sciences is invalid, unenforceable and/or will not be infringed by Natco's manufacture, use or sale of the product described in its ANDA submission.

Gilead is currently reviewing the Notice Letter and has 45 days from the date of receipt to commence a patent infringement lawsuit against Natco. Such a lawsuit would restrict the FDA from approving Tamiflu's ANDA for up to 30 months or until a district court decision that is adverse to Gilead, whichever occurs first. Tamiflu is protected by this patent, which is listed in the FDA's Approved Drug Products List, and the patent would need to be invalidated or not infringed upon before a generic version of Tamiflu could be marketed without liability for patent infringement.

Tamiflu was invented by Gilead Sciences and licensed to F. Hoffmann-La Roche Ltd in 1996.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

share



Related Articles